AbbVie Inc. (NYSE: ABBV) is trading near recent highs on Monday, December 22, 2025, as investors weigh a powerful mix of policy risk, shareholder returns, and pipeline momentum heading into 2026.
The big near-term variable isn’t a clinical readout—it’s Washington. After the White House unveiled sweeping “most-favored-nation” (MFN) drug-pricing agreements with nine large manufacturers on December 19, AbbVie remains one of the last major drugmakers still outside the deal. [1]
At the same time, AbbVie’s core fundamentals continue to be anchored by its immunology franchise—Skyrizi and Rinvoq—alongside a rising dividend profile and a pipeline that includes late-stage programs in neuroscience and oncology. [2]
ABBV stock price today: Where AbbVie shares stand on Dec. 22, 2025
As of 16:59 UTC on Dec. 22 (midday in U.S. trading), ABBV was at $227.73, modestly higher on the session, with an intraday range roughly in the mid-$224s to upper-$227s.
Price action has also been supported by recent strength in the broader pharma group, which has outperformed the wider market in 2025, according to Reuters’ reporting on sector performance. [3]
The headline risk for AbbVie stock: MFN drug-pricing agreements and “TrumpRx”
What happened
On December 19, 2025, the White House announced nine new drug-pricing agreements tied to MFN pricing—intended to align certain U.S. prices with the lowest prices paid in other developed nations. The White House list of participating manufacturers includes Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis, and Sanofi. [4]
Reuters reported that, after these deals, AbbVie is one of three large companies still not signed (alongside Johnson & Johnson and Regeneron). [5]
Why it matters to ABBV investors
For AbbVie shareholders, the market focus is twofold:
- Whether AbbVie ultimately signs—and on what terms.
Earlier in the week, Reuters reported AbbVie and other drugmakers were expected to announce agreements, underscoring how fluid the situation has been. [6] - Whether MFN-style commitments extend beyond narrow channels.
Reuters’ Dec. 19 report says drugmakers committed to MFN pricing on all new U.S. drug launches across commercial, government, and cash-pay markets for participating companies—language that raises the stakes if similar expectations are applied more broadly. [7]
What AbbVie has already said about pricing pressure
Drug pricing has been a recurring theme in AbbVie coverage this year. In late October, Reuters reported AbbVie said the Trump administration was pushing for steeper Medicare drug price negotiation cuts, while AbbVie indicated the negotiated cuts (effective later) would not change its long-term guidance. [8]
Bottom line: policy uncertainty is the most immediate swing factor for ABBV sentiment into year-end and early 2026—especially because AbbVie is still “outside the tent” after the Dec. 19 announcement. [9]
AbbVie’s fundamental engine: Skyrizi and Rinvoq keep carrying the post-Humira transition
The investment case for AbbVie in late 2025 continues to revolve around the company’s ability to replace Humira-era cash flows with a newer growth portfolio—especially Skyrizi and Rinvoq.
Reuters’ coverage of AbbVie’s third-quarter results highlights how central these drugs have become:
- Skyrizi Q3 sales:$4.71 billion
- Rinvoq Q3 sales:$2.18 billion
- Q3 revenue:$15.78 billion
- Q3 adjusted EPS:$1.86 [10]
AbbVie also raised full-year 2025 adjusted EPS guidance to $10.61–$10.65 in its Q3 financial results release distributed via PRNewswire. [11]
On the top line, Fierce Pharma reported AbbVie lifted its 2025 revenue outlook to $60.9 billion, crediting continued strength in Skyrizi and Rinvoq. [12]
Meanwhile, a Nasdaq analysis piece noted AbbVie expects combined Skyrizi and Rinvoq sales to surpass $25 billion in 2025, reinforcing why investors often treat ABBV as an immunology-led growth-and-income hybrid rather than a slow-moving “legacy pharma” name. [13]
The watch-out: Aesthetics softness is still a headline risk
Not every segment is firing at the same rate. Reuters noted AbbVie’s aesthetics portfolio has been a weak point (including Botox in the aesthetics segment), with executives pointing to economic and inflation pressures affecting demand. [14]
Dividend and income outlook: AbbVie boosts the payout to $1.73 quarterly
For investors who follow AbbVie for income, the latest dividend details remain a meaningful pillar of the ABBV story.
In its Q3 2025 financial results release, AbbVie said its board approved a 5.5% increase in the quarterly dividend:
- Quarterly dividend:$1.73 per share (up from $1.64)
- Payable:February 17, 2026
- Shareholder record date:January 16, 2026 [15]
StockAnalysis lists AbbVie’s annualized dividend at $6.92 and shows the next ex-dividend date as Jan. 16, 2026, with the dividend paid quarterly. [16]
This matters for Google Discover–style audiences because it’s a simple framing: ABBV is not only a pipeline story—it’s also a cash-return story, and the next dividend milestone is already on the calendar. [17]
Pipeline and 2026 catalysts: Rinvoq expansion, Parkinson’s filing, and oncology programs under review
While Washington drives the near-term tape, AbbVie’s medium-term narrative is still built on product-cycle execution. Recent coverage has pointed to multiple potential catalysts.
1) Rinvoq label expansions: multiple shots on goal
A Nasdaq pipeline-focused report said AbbVie is pursuing Rinvoq expansion across additional indications—including systemic lupus erythematosus, hidradenitis suppurativa, vitiligo, alopecia areata, and Takayasu arteritis—and suggested AbbVie believes these could add meaningful peak-sales potential over time. [18]
2) Neuroscience: Tavapadon filing for Parkinson’s disease
The same Nasdaq report states AbbVie submitted a regulatory filing seeking approval for tavapadon as a once-daily oral Parkinson’s treatment, supported by data from three late-stage studies. [19]
AbbVie’s own pipeline page (updated September 8, 2025) lists tavapadon in the pipeline for Parkinson’s disease, reflecting the company’s broader push to deepen its neuroscience portfolio. [20]
3) Oncology: EPKINLY approval and more in the queue
AbbVie announced in November that the FDA approved EPKINLY (epcoritamab-bysp) in combination with rituximab and lenalidomide for certain adults with relapsed or refractory follicular lymphoma, a notable win in hematologic oncology. [21]
Separately, the Nasdaq pipeline report points to pivekimab sunirine (PVEK) as being under FDA review for BPDCN (a rare blood cancer), which—if approved—would expand AbbVie’s oncology toolkit further. [22]
Wall Street forecast for AbbVie stock: price targets and the range of expectations
Analyst outlooks remain generally constructive, but they’re not uniform—typical for a mega-cap pharma name facing both policy uncertainty and product-cycle opportunity.
StockAnalysis, which aggregates analyst forecasts, lists:
- Consensus rating: Buy
- Average price target:$242.28
- High / low targets:$289 / $190 [23]
Benzinga’s analyst compilation shows a somewhat lower consensus target ($234.37) while still describing a generally positive stance (Overweight/positive leaning), and it notes recent rating activity from large banks in December. [24]
The practical takeaway for readers: ABBV is priced close enough to its target cluster that policy clarity and execution updates may matter more than incremental quarterly beats. [25]
What to watch next for ABBV (near-term checklist)
Heading out of Dec. 22, the most important moving pieces for AbbVie stock watchers are:
- Any update on whether AbbVie joins the MFN/TrumpRx agreement framework after the White House’s Dec. 19 round of announcements—especially since Reuters reported AbbVie remains one of the final three not yet signed. [26]
- Follow-through on Rinvoq and neuroscience milestones highlighted in pipeline coverage (including tavapadon). [27]
- Dividend timeline into early 2026, with the next key date in mid-January and payment in mid-February. [28]
- Next earnings timing: market calendars commonly estimate a late-January window for AbbVie’s next report, but dates can shift until the company confirms. [29]
The bottom line on AbbVie stock on Dec. 22, 2025
As of Dec. 22, 2025, AbbVie stock sits at an intersection of policy headlines and fundamental execution:
- The largest near-term risk driver is U.S. drug pricing policy—particularly the MFN framework and the fact that AbbVie is still among the last large manufacturers outside the newly announced agreements. [30]
- The core bull case remains Skyrizi + Rinvoq durability, plus a broadening pipeline and a dividend that continues to climb. [31]
References
1. www.whitehouse.gov, 2. www.reuters.com, 3. www.reuters.com, 4. www.whitehouse.gov, 5. www.reuters.com, 6. www.reuters.com, 7. www.reuters.com, 8. www.reuters.com, 9. www.reuters.com, 10. www.reuters.com, 11. www.prnewswire.com, 12. www.fiercepharma.com, 13. www.nasdaq.com, 14. www.reuters.com, 15. www.prnewswire.com, 16. stockanalysis.com, 17. www.prnewswire.com, 18. www.nasdaq.com, 19. www.nasdaq.com, 20. www.abbvie.com, 21. news.abbvie.com, 22. www.nasdaq.com, 23. stockanalysis.com, 24. www.benzinga.com, 25. www.reuters.com, 26. www.reuters.com, 27. www.nasdaq.com, 28. www.prnewswire.com, 29. www.marketbeat.com, 30. www.reuters.com, 31. www.reuters.com
